ASH 2023 | First-in-human trial of CLN-978, a novel CD19 bispecific antibody, for the treatment of R/R B-NHL
Geoffrey Shouse
• 11 Dec 2023
Geoffrey Shouse, DO, PhD, City of Hope, Duarte, CA, introduces a Phase I first-in-human dose escalation and expansion study (NCT05879744) of a novel CD19 bispecific antibody, CLN-978, for the treatment of relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL). This antibody has an additional binding site for human serum albumin (HSA), allowing for half-life extension. This circumvents the need for a continuous dosing strategy, such as that used when treating patients with blinatumomab. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
